Skip to main content
Clinical Trials/EUCTR2020-001606-33-ES
EUCTR2020-001606-33-ES
Active, not recruiting
Phase 1

Randomized clinical trial to evaluate the efficacy of hydroxychloroquine associated or not with azithromycin as a treatment for COVID-19 infection. - Randomized clinical trial to evaluate the efficacy of a treatment for COVID-19 infection

Instituto Investigación Sanitario Biocruces Bizkaia0 sites132 target enrollmentApril 7, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
COVID-19 infection
Sponsor
Instituto Investigación Sanitario Biocruces Bizkaia
Enrollment
132
Status
Active, not recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 7, 2020
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Instituto Investigación Sanitario Biocruces Bizkaia

Eligibility Criteria

Inclusion Criteria

  • \- Patients of both sexes
  • \- Patients \= 18 years with COVID and comorbidities (COPD, asthma, heart disease, HT, diabetes, neoplasia, chronic liver disease or with immunosuppressive treatment), without pneumonia or over 60 with COVID
  • \- SARS\-CoV\-2 infection confirmed by PCR test
  • \- Radiographic evidence of not presenting pneumonia
  • \- O2 saturation\> 92%
  • \- Respiratory Rate \<20 rpm
  • \- Willing and able to sign the written informed consent before carrying out the study procedures. Exceptionally, oral consent is admitted, preferably before independent witnesses, documenting it in the medical record and provided that it can later be ratified.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes

Exclusion Criteria

  • \- Participation in any other clinical trial with an experimental treatment for COVID\-19
  • \- Hypersensitivity to the active substance, to 4\-aminoquinoline compounds or to any of the excipients included in section 6\.1 of the hydroxychloroquine data sheet
  • \- Hypersensitivity to azithromycin, erythromycin, any other macrolide or ketolide antibiotic or to any of the excipients listed in section 6\.1 of the azithromycin SmPC
  • \- psoriasis
  • \- Patients with glucose\-6\-phosphate dehydrogenase deficiency
  • \- Any contraindication according to the Technical Data Sheet of Hydroxychloroquine and Azithromycin
  • \- pneumonia
  • \- Myasthenia gravis
  • \- Pre\-existing maculopathy of the eye
  • \- Presence of changes in acuity or visual field

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Study to evaluate the use of supplemental oxygen in patients with acute symptomatic pulmonary embolism.Acute symptomatic pulmonary embolismTherapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
EUCTR2019-000266-37-ESFundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal100
Active, not recruiting
Phase 1
Randomized study to evaluate the efficacy of two techniques against chronic hip pain: radiofrequency over sensitive nerves of the hip, compared injection of steroids and local anestethic into the hip.Chronic Hip Pain by OsteoarthrosisTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
EUCTR2018-000269-36-ESJORGE ORDUÑA VALLS20
Not yet recruiting
Phase 2
Pumpkin (Bhopala) on mental capacity in malnourished children.Health Condition 1: R419- Unspecified symptoms and signs involving cognitive functions and awarenessHealth Condition 2: R419- Unspecified symptoms and signs involving cognitive functions and awareness
CTRI/2023/02/049381Dr Sarita S Neeralakeri
Active, not recruiting
Phase 1
Study to evaluate the efficacy of fibrin membrane graft with eye drops concentrated in autologous growth factors in primary pterygium surgery comparing it with amniotic membrane graftPterigyumTherapeutic area: Body processes [G] - Ocular Physiological Phenomena [G14]
EUCTR2018-003042-16-ESInstitut de Recerca H. de la Santa Creu i Sant Pau110
Active, not recruiting
Phase 1
Efficacy of different treatments in patients infected with COVID-19Patients infected with COVID19Therapeutic area: Diseases [C] - Virus Diseases [C02]
EUCTR2020-001156-18-ESFundación para la investigación Biomedica Hospital Universitario La Paz1,000